37.76 +0.09 (0.24%)
Pre-Market: 7:00AM EDT
|Bid||37.52 x 800|
|Ask||37.69 x 900|
|Day's Range||37.45 - 37.77|
|52 Week Range||32.32 - 39.43|
|PE Ratio (TTM)||10.46|
|Earnings Date||Jul 31, 2018|
|Forward Dividend & Yield||1.36 (3.66%)|
|1y Target Est||39.80|
London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.
An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday. The study showed ...
Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
Novartis (NOVN.S) expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer (PFE.N) in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.
Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump criticized the company over reported plans to raise them.
Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.
Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies need to lower the prices they charge.
New Brunswick, N.J.-based Johnson & Johnson (NYSE: JNJ) is probably most famous as the parent company of multiple household products that double as household names. If you’ve ever bandaged a wound, rinsed your mouth, applied lotion, sanitized your hands, battled a headache, substituted sugar or treated heartburn, chances are excellent that you did so courtesy of Johnson & Johnson’s research and development. To quote company Chairman and CEO Alex Gorsky, “approximately 70% of our sales come from products with the number one or number two global market share position.” Johnson & Johnson boasts no fewer than 275 subsidiary companies, up from 250 three years ago.
Some drug companies continue to raise prices, despite mounting public scrutiny and pressure from the president. Pfizer raised the price of more than 40 medications at the beginning of July. "The pharmaceutical industry is very much addicted to price inflation in terms of growth," said analyst Elliot Wilbur.
The two companies, which said a licensing deal in 2014, have completed the transfer of the therapy's development from Spark to Pfizer.
UAB researchers have made a significant discovery in diabetes research – one that could reduce the skyrocketing costs of treatment.
Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.
Pfizer Inc. (PFE) and Spark Therapeutics (ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the next part of the Phase 3 study, which will evaluate the investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B. The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study.
The drugmaker's second reorganization in four years signals where the company is headed. But it doesn't solve its most serious problem.
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
A small Colorado drugmaker recently raised the price for a spray form of sleep aid Ambien by as much as 843%, the latest example of how some firms are increasing prices despite mounting pressure. The median price increase is 8%, but some specific increases have been far greater. Aytu BioScience Inc. raised the list price of a 7.7 milliliter bottle of its sleep aid Zolpimist to $659 from $69.88, while increasing the price of a 4.5 milliliter bottle by 747% to $329.50, according to RELX PLC’s Elsevier Gold Standard Drug Database.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC. This approval makes XTANDI the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC TOKYO and NEW YORK , July 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ...
Did you ever copy from the smart kid in class and then score straight A’s? Well, now you can replicate this savvy move with top investor trades — and make some money while you’re at it!
Elliot Wilbur, Raymond James specialty pharmaceuticals analyst, discusses the rising cost of prescription drugs and how President Trump is tackling the issue.